Last reviewed · How we verify

Adrenocorticotrophic hormone

University of Ottawa · Phase 3 active Small molecule

Adrenocorticotrophic hormone (ACTH) stimulates the adrenal cortex to produce and release cortisol and other corticosteroids.

Adrenocorticotrophic hormone (ACTH) stimulates the adrenal cortex to produce and release cortisol and other corticosteroids. Used for Adrenocortical insufficiency, Infantile spasms (West syndrome), Autoimmune and inflammatory conditions.

At a glance

Generic nameAdrenocorticotrophic hormone
Also known asACTH
SponsorUniversity of Ottawa
Drug classPeptide hormone
TargetMelanocortin-2 receptor (MC2R)
ModalitySmall molecule
Therapeutic areaEndocrinology / Immunology
PhasePhase 3

Mechanism of action

ACTH is a peptide hormone that binds to melanocortin-2 receptors on adrenocortical cells, triggering a cascade that increases synthesis and secretion of glucocorticoids (cortisol), mineralocorticoids (aldosterone), and adrenal androgens. This endogenous hormone replacement or supplementation approach restores or enhances the hypothalamic-pituitary-adrenal (HPA) axis function in conditions of adrenal insufficiency or immune dysregulation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: